

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00
OR CREDIT ANY EXCESS IN THE FEES DUE WITH
THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 19-0365

File No. AL01678K US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hey et al.

Serial No.: 10/767,164

Group Art Unit: TBA

Filed: January 29, 2004

Examiner: TBA

For: METHODS FOR TREATING ALLERGIC SKIN AND ALLERGIC OCULAR
CONDITIONS USING COMBINATIONS OF HISTAMINE RECEPTOR ANTAGONISTS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


This statement is made in compliance with 37 C.F.R. §1.56, 1.97 and 1.98. The Examiner's attention is directed to the documents listed on the accompanying form PTO-1449 and the enclosed copy of each listed document. Consideration of each cited document, and the return of an initialed, duplicate copy of the enclosed form PTO-1449 to indicate such consideration, are respectfully requested.

These documents may be relevant to examination of the application. Inclusion of a document is **not** an admission that the document is prior art with respect to the invention of the application and is **not** to be construed as an admission that anything in the document renders any claim of the application unpatentable.

This statement is submitted before a first office action on the merits of the Application; accordingly, Applicants believe that no fee is required. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365.

Date: May 17, 2004

Respectfully submitted,


Thomas Triolo, Ph.D.
Registration No. 48,001
Agent for Applicant(s)

Schering-Plough Corporation
Patent Department; K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033
908-298-2347

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
AL01678-K-USSERIAL NO.:
10/767,164INFORMATION DISCLOSURE STATEMENT
FOR PATENT

Use several sheets if necessary)

APPLICANT:
Hey *et al.*FILING DATE:
January 29, 2004GROUP:
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
AA	5,869,479	Feb. 9, 1999	Kreutner <i>et al.</i>	514	212	Aug. 14, 1997
AB						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO
AC	WO 02/32893	Apr. 25, 2002	WIPO	C07D	401/00		
AD	WO 03/88967	Oct. 30, 2003	WIPO	A61K	31/454 5		
AE							
AF							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AG	Cook <i>et al.</i> , "Lack of effect of cimetidine in chronic-idiopathic urticaria" Acta Dermatovener (Stockholm) 63: 265-267 (1993)	✓
AH	McLeod <i>et al.</i> , "Histamine H3 antagonists" Prog. Respir. Res. Basel, Karger 31:133-136 (2001)	✓
AI	Arrang <i>et al.</i> , "Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor" Nature 302(5911):832-837 (1983).	✓
AJ	McLeod <i>et al.</i> , "Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion" American Journal of Rhinology 13(5):391-399 (1999).	✓
AK	McLeod <i>et al.</i> , "Hemodynamic profile of activation of histamine H3 receptors by R-alpha-methylhistamine in the guinea pig" Gen Pharmacol. 27(6):1001-1007 (1996)	✓
AL	Simons <i>et al.</i> , "The pharmacology and use of H1-receptor-antagonist drugs" N. Engl. J. Med. 330(23):1663-1670 (1994).	
AM	Simons <i>et al.</i> , "Peripheral H1-blockade effect of fexofenadine" Ann Allergy Asthma Immunol. 79(6):530-532 (1997).	
AN	Kaur <i>et al.</i> , "Factitious urticaria (dermographism): treatment by cimetidine and chlorpheniramine in a randomized double-blind study" Br. J. Dermatol. 104(2):185-190 (1981).	
AO	Commens <i>et al.</i> , "Cimetidine in chronic idiopathic urticaria: a randomized double-blind study" Br J. Dermatol. 99(6):675-679 (1978).	
AP	Marks <i>et al.</i> , "Vascular reactions to histamine and compound 48/80 in human skin: suppression by a histamine H2-receptor blocking agent" Br. J. Clin. Pharmacol. 4(3):367-369 (1977).	
AQ	Kavanagh <i>et al.</i> , "The intradermal effects of the H3 receptor agonist R alpha methylhistamine in human skin" Br. J. Dermatol. 138(4):622-626 (1998).	
AR	Bleehen <i>et al.</i> , "Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study" Br. J. Dermatol. 117(1):81-88 (1987).	
AS	Monroe <i>et al.</i> , "Combined H1 and H2 antihistamine therapy in chronic urticaria" Arch. Dermatol. 117(7):404-407 (1981).	
AT	Ormerod, "Urticaria. Recognition, causes and treatment" Drugs 48(5):717-730 (1994).	
AU	Phanuphak <i>et al.</i> , "Treatment of chronic idiopathic urticaria with combined H1 and H2 blockers" Clin. Allergy 8(5):429-33 (1978).	
AV	Miller <i>et al.</i> , "Suppression of immediate skin tests by ranitidine" J. Allergy Clin. Immunol. 84(6 Pt 1):895-899 (1989).	

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: AL01678-K-US	SERIAL NO.: 10/767164
INFORMATION DISCLOSURE STATEMENT FOR PATENT <i>(Use several sheets if necessary)</i>				APPLICANT: Hey <i>et al.</i>	
				FILING DATE: January 29, 2004	GROUP: To be assigned
U.S. PATENT DOCUMENTS					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	AW	Mansfield <i>et al.</i> , "Greater inhibition of dermographia with a combination of H1 and H2 antagonists" Ann. Allergy. 50(4):264-5 (1983).			
	AX	Paul <i>et al.</i> , "Treatment of chronic urticaria with terferadine and ranitidine" European Journal of Clin Pharmacology 31:277-280 (1986).			
	AY	Monroe, "Nonsedating H1 antihistamines in chronic urticaria" Ann. Allergy. 71(6):585-591 (1993).			
	AZ	Tozzi <i>et al.</i> , "The pharmacology of azatadine, a potential antiallergy drug" Agents Actions. 4(4):264-270 (1974).			
	BA	Smith <i>et al.</i> , "Cutaneous responses to vasoactive intestinal polypeptide in chronic idiopathic urticaria" The Lancet 339:91-93 (1992).			
	BB	Goldberg <i>et al.</i> , "Cutaneous responses to histamine, compound 48/80 and codeine in patients with hyperthyroidism" Ann. Allergy. 64(2 Pt 1):179-181 (1990).			
	BC				
	BD				
	BE				
	BF				
	BG				
	BH				
	BI				
	BJ				
EXAMINER			DATE CONSIDERED		
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					